Refine
Has Fulltext
- yes (30)
Is part of the Bibliography
- yes (30)
Year of publication
Document Type
- Journal article (30)
Language
- English (30)
Keywords
- CXCR4 (10)
- PET (8)
- theranostics (8)
- molecular imaging (5)
- PRRT (4)
- adrenocortical carcinoma (4)
- chemokine receptor (4)
- multiple myeloma (4)
- PET/CT (3)
- endoradiotherapy (3)
- fibroblast activation protein (3)
- prostate cancer (3)
- radioligand therapy (3)
- C-X-C motif chemokine receptor 4 (2)
- DOTATOC (2)
- NET (2)
- PSMA (2)
- SSTR (2)
- [68Ga]PentixaFor (2)
- head and neck cancer (2)
- medicine (2)
- radionuclide therapy (2)
- sarcoidosis (2)
- somatostatin receptor (2)
- 11C-Methionine PET/CT (1)
- 18F-FDG PET/CT (1)
- 68Ga-PSMA ligand PET/CT (1)
- 68Ga-Pentixafor PET/CT (1)
- Arginine (1)
- COVID-19 (1)
- CTNNB1 (1)
- CXCR4-targeting (1)
- CXCR4/SDF-1 (1)
- CXCR7 (1)
- CYP11B enzymes (1)
- Cushing’s disease (1)
- Cushing’s syndrome (1)
- DOTA-EB-TATE (1)
- FDG (1)
- FDG PET/CT (1)
- Hyperkalaemia (1)
- IMAZA (1)
- Lysine (1)
- MAG3 (1)
- Merkel cell carcinoma (1)
- Molecular imaging (1)
- NR3C1 (1)
- PSMA I&T (1)
- PSMA-617 (1)
- Pentixafor (1)
- Positron emission tomography (1)
- Positronen-Emissions-Tomografie (1)
- SARS-CoV-2 (1)
- Somatostatin receptor expression (1)
- USP28 (1)
- USP8 (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]Lu-PSMA I&T (1)
- [177Lu]PentixaTher (1)
- [68Ga]Pentixafor (1)
- [90Y]PentixaTher (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- adrenal incidentaloma (1)
- agreement (1)
- amino acids (1)
- androgen deprivation therapy (1)
- autologous transplantation (1)
- biokinetics (1)
- biomarker (1)
- bone disease (1)
- buparlisib (1)
- c-MYC (1)
- cancer (1)
- cells (1)
- comparability (1)
- detection rate (1)
- evans blue (1)
- gefitinib (1)
- glucocorticoid excess (1)
- hypercortisolism (1)
- hyperkalemia (1)
- in vivo imaging (1)
- intraindividual comparison (1)
- involvement (1)
- kidney function (1)
- lung cancer (1)
- malignancies (1)
- matched pair (1)
- metabolic tumour volume (MTV) (1)
- microenvironment (1)
- neuroendocrine tumor (1)
- overall survival (1)
- peptide receptor (1)
- peptide receptor radionuclide therapy (1)
- pleural mesothelioma (1)
- positron emission tomography (1)
- prediction (1)
- prognosis (1)
- prostate-specific membrane antigen (1)
- prostate-specific membrane antigen (PSMA) (1)
- recurrence (1)
- recurrent prostate cancer (1)
- salvage radiotherapy (1)
- smoldering myeloma (1)
- software (1)
- solid tumors (1)
- somatostatin receptors (1)
- survival (1)
- total lesion PSMA (1)
- vemurafenib (1)
- vestibular schwannoma (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (30)
- Pathologisches Institut (9)
- Medizinische Klinik und Poliklinik I (8)
- Medizinische Klinik und Poliklinik II (7)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (6)
- Urologische Klinik und Poliklinik (5)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Comprehensive Cancer Center Mainfranken (2)
- Institut für Klinische Biochemie und Pathobiochemie (2)
- Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen (2)
- Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie (2)
- Institut für Klinische Transfusionsmedizin und Hämotherapie (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
- Lehrstuhl für Biochemie (1)
- Neurochirurgische Klinik und Poliklinik (1)
- Theodor-Boveri-Institut für Biowissenschaften (1)
EU-Project number / Contract (GA) number
- 701983 (1)
Adrenocortical carcinoma (ACC) represents a rare tumor entity with limited treatment options and usually rapid tumor progression in case of metastatic disease. As further treatment options are needed and ACC metastases are sensitive to external beam radiation, novel theranostic approaches could complement established therapeutic concepts. Recent developments focus on targeting adrenal cortex-specific enzymes like the theranostic twin [\(^{123/131}\)I]IMAZA that shows a good image quality and a promising therapeutic effect in selected patients. But other established molecular targets in nuclear medicine such as the C-X-C motif chemokine receptor 4 (CXCR4) could possibly enhance the therapeutic regimen as well in a subgroup of patients. The aims of this review are to give an overview of innovative radiopharmaceuticals for the treatment of ACC and to present the different molecular targets, as well as to show future perspectives for further developments since a radiopharmaceutical with a broad application range is still warranted.